RayKnowChina Research Map
Shortlist

Blood disorders

Lymphoma in Nanjing

南京 淋巴瘤

All diseases in Nanjing

6 hospitals in Nanjing

Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for lymphoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Nanjing may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 81 papers led
  2. 20 papers led
    No open trial led
  3. 7 papers led
    No open trial led
  4. 6 papers led
    No open trial led
  5. 6 papers led
    No open trial led
  6. 5 papers led
    No open trial led

Lymphoma in every city Nanjing on the disease page, with the national map

48

open trials on lymphoma with a hospital in Nanjing

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Nanjing as lead sponsor or study site. 19 of them are led by a hospital in Nanjing. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07409428

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07410520

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  3. Recruiting
    Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07418190

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  4. Recruiting
    Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07496229

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengdu, Chongqing, Fuzhou, Nanjing, Nanning, Shanghai, Taiyuan, Wenzhou, Wuhan, Zhengzhou

  5. Recruiting
    Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07608978

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  6. Recruiting
    A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07609823

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  7. Recruiting
    Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07719556

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 1 listed hospital as study siteChangzhou, Nanjing

  8. Recruiting
    A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06742996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Wenzhou, Wuhan, Xuzhou, Zhengzhou

  9. Recruiting
    UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
    Phase
    Phase 1
    Started
    2025-04
    Posted
    Registry
    NCT06743503

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Tianjin

  10. Recruiting
    Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06854445

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangsha, Dalian, Hangzhou, Harbin, Jinan, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Shijiazhuang, Suzhou, Taiyuan, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou

  11. Recruiting
    A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06943872

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hohhot, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Wuxi, Xiamen, Yangzhou

  12. Recruiting
    Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT06958705

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  13. Recruiting
    A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07082686

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  14. Recruiting
    Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
    Phase
    N/A
    Started
    2025-07
    Posted
    Registry
    NCT07126678

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  15. Recruiting
    A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07139873

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Tianjin

  16. Recruiting
    PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07188610

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Shanghai, Suzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou

  17. Recruiting
    A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07189065

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou

  18. Recruiting
    Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07208981

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  19. Recruiting
    The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07240194

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  20. Recruiting
    Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT07448324

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  21. Recruiting
    A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06363994

    Age 60 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  22. Recruiting
    ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
    Phase
    Phase 2/Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06378138

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi

  23. Recruiting
    DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06539182

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  24. Recruiting
    Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06891157

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  25. Recruiting
    Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT07195799

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  26. Recruiting
    A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT07234162

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  27. Recruiting
    A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Posted
    Registry
    NCT05800977

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Tianjin, Zhengzhou

  28. Recruiting
    A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05931263

    Age 18 years to 65 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  29. Recruiting
    A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06136559

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Taiyuan, Tianjin, Urumqi, Wuhan, Xuzhou, Zhengzhou

  30. Recruiting
    Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
    Phase
    Phase 1/Phase 2
    Started
    2022-05
    Posted
    Registry
    NCT05294731

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Suzhou, Taiyuan, Wenzhou, Wuhan, Zhengzhou

  31. Recruiting
    Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
    Phase
    Phase 2
    Started
    2021-04
    Posted
    Registry
    NCT04728893

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou

  32. Recruiting
    Evaluate the Safety and Clinical Activity of HH2853
    Phase
    Phase 1/Phase 2
    Started
    2020-09
    Posted
    Registry
    NCT04390737

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou

  33. Recruiting
    Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
    Phase
    Phase 1/Phase 2
    Started
    2020-08
    Posted
    Registry
    NCT04494503

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan

  34. Recruiting
    A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
    Phase
    Phase 1
    Started
    2018-04
    Posted
    Registry
    NCT03460977

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chengdu, Guangzhou, Nanjing, Wenzhou

  35. Not yet recruiting
    SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07347288

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  36. Not yet recruiting
    Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07744724

    Age 18 years to 65 years (registered criteria)

    Led by Changzhou No.2 People's Hospital; 1 listed hospital as study siteChangzhou, Nanjing

  37. Not yet recruiting
    Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07744737

    Age 18 years to 80 years (registered criteria)

    Led by Changzhou No.2 People's Hospital; 1 listed hospital as study siteChangzhou, Nanjing

  38. Not yet recruiting
    Pirtobrutinib+Sonrotoclax(PS) Regimen in the Treatment of B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07744750

    Age 18 years to Not stated (registered criteria)

    Led by Changzhou No.2 People's Hospital; 1 listed hospital as study siteChangzhou, Nanjing

  39. Not yet recruiting
    The Efficacy of CAPCT in Patients With PTCL
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07746245

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  40. Not yet recruiting
    R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07764601

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangzhou, Nanjing

  41. Not yet recruiting
    A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07784101

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  42. Not yet recruiting
    Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma
    Phase
    Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07888621

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  43. Not yet recruiting
    Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07896590

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

  44. Not yet recruiting
    Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT06925555

    Age 18 years to 70 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  45. Not yet recruiting
    RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-08
    Posted
    Registry
    NCT07113496

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  46. Not yet recruiting
    Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07187960

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chongqing, Guiyang, Haikou, Lanzhou, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yantai, Zhengzhou

  47. Not yet recruiting
    Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06594432

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  48. Not yet recruiting
    A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma
    Phase
    N/A
    Started
    2022-06
    Posted
    Registry
    NCT05343377

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Nanjing

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Nanjing, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerLung cancerPancreatic cancerBreast cancerGliomaHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisLymphomaBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaCoronary heart diseaseCongenital heart diseaseScoliosisAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Affiliated BenQ Hospital of Nanjing Medical University南京明基医院nonenonenonenonenonenonenonenonenonenonenone1none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Brain Hospital of Nanjing Medical University南京脑科医院nonenonenonenone45nonenone21nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone3nonenone2nonenonenonenonenone5nonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Eye Hospital of Nanjing Medical University南京医科大学眼科医院nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Hospital of Nanjing University南京大学医学院附属鼓楼医院nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Hospital of Nanjing University of Chinese Medicine南京中医药大学附属医院nonenonenone21none18nonenonenonenonenone20nonenonenonenonenonenone6nonenonenonenonenonenonenonenonenonenonenone6nonenonenonenonenone3nonenonenonenonenonenonenonenone1nonenonenone1nonenonenonenonenonenonenonenonenonenone
Affiliated Hospital, Nanjing Medical University南京医科大学附属口腔医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenone
Affiliated Hospital, Nanjing University of Chinese Medicine江苏省中西医结合医院nonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Hospital, Nanjing University of Traditional Chinese Medicine江苏省中医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenone1nonenonenonenonenonenonenonenonenonenone
Affiliated Jiangning Hospital, Nanjing Medical University南京市江宁医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Jiangsu Shengze Hospital of Nanjing Medical University江苏盛泽医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Lianyungang Hospital of Xuzhou Medical University连云港市第一人民医院nonenonenonenonenonenonenonenonenonenonenonenonenone2none4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated People's Hospital of Jiangsu University江苏大学附属人民医院nonenonenone21nonenonenonenonenonenonenone1none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Yancheng Hospital, Southeast University盐城市第三人民医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Children's Hospital of Nanjing Medical University南京市儿童医院nonenonenonenonenonenonenonenone3nonenone1none151 opennonenone1nonenonenonenone0nonenonenonenonenonenonenonenone9none23none1nonenone0nonenonenone0none02010nonenonenonenonenone9nonenone0nonenonenonenone
Fourth Affiliated Hospital of Nanjing Medical University南京医科大学第四附属医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Gaochun People's Hospital南京市高淳人民医院nonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jiangsu Cancer Hospital江苏省肿瘤医院141 open252 open16261233 open6471 open15nonenonenone00nonenonenonenonenonenone6nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenone
JiangSu Provincce Hospital江苏省人民医院nonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jiangsu Province Hospital江苏省人民医院(南医大一附院)11368 open1175 open19923 open2335 open914 open25025 open59none014141 open82 open0246 open01 open9228119 open10nonenonenonenonenone433 opennonenone10115 open18nonenone2none10none4none1none10none21none101none00021nonenonenone
Jiangsu Provincial People's Hospital江苏省人民医院(南京医科大学第一附属医院)nonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jiangyin Hospital, Nanjing University of Chinese Medicine江阴市中医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jinling Hospital东部战区总医院(金陵医院)none9231 open201 open76113 open1924none0none140nonenone41 opennonenonenone5nonenone01nonenone01 opennonenonenonenone242 open2nonenonenonenone2none2nonenonenonenonenone510nonenone0nonenonenone00none1nonenonenonenone
Nanjing Bayi Hospital中国人民解放军第八一医院nonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Nanjing Chest Hospitalnonenonenonenone25nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Nanjing Drum Tower Hospital南京鼓楼医院213952 open1133 open811 open635 open4518nonenonenone8121none17nonenonenone20none2nonenonenone0none27nonenone121 open8821 opennone1none31none0none0nonenone0none3nonenone011nonenone01nonenonenonenonenone
Nanjing Drum Town Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Nanjing First Hospital南京市第一医院nonenonenonenonenonenonenonenonenonenonenone0none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Nanjing Jiangbei Hospital南京江北医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Nanjing Pukou District Hospital南京市浦口人民医院nonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Nanjing Second Hospital南京市第二医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenone30nonenonenonenonenonenonenonenonenone
Nanjing Stomatological Hospital南京市口腔医院nonenonenonenonenonenonenonenonenonenonenone0nonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Nanjing Tianyinshan Hospital南京天印山医院nonenone11 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Affiliated Hospital of Nanjing Medical University南京医科大学第二附属医院0none191 open122361 opennonenonenonenone1321nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenone8nonenonenonenone11none1nonenonenonenone1none1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Hospital, Nanjing University of Chinese Medicine江苏省第二中医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenone
Shuyang Hospital, Nanjing University of Chinese Medicine沭阳县中医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Sir Run Run Hospital南京医科大学附属逸夫医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Third Affiliated Hospital of Nanjing University of Chinese Medicine南京市中医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenone16nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Women's Hospital, Nanjing Medical University南京市妇幼保健院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenone4nonenonenonenonenonenonenonenone1none2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Yancheng First Hospital, Nanjing University盐城市第一人民医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Yancheng TCM Hospital, Nanjing University of Chinese Medicine盐城市中医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Zhongda Hospital, Southeast University东南大学附属中大医院none18599 open211 open47222412none10312240nonenone7nonenonenone1nonenonenonenonenonenonenone3432nonenonenone1none1none0nonenonenonenone3nonenonenone1none1nonenonenonenonenonenonenonenone

Column labels are short names. Choose one to open that disease in Nanjing.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for lymphoma.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Nanjing on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data